Pacira BioSciences (PCRX) EBIAT (2016 - 2025)
Historic EBIAT for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $5.4 million.
- Pacira BioSciences' EBIAT rose 10378.63% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 12362.81%. This contributed to the annual value of -$99.6 million for FY2024, which is 33730.19% down from last year.
- Pacira BioSciences' EBIAT amounted to $5.4 million in Q3 2025, which was up 10378.63% from -$4.8 million recorded in Q2 2025.
- Over the past 5 years, Pacira BioSciences' EBIAT peaked at $25.8 million during Q2 2023, and registered a low of -$143.5 million during Q3 2024.
- In the last 5 years, Pacira BioSciences' EBIAT had a median value of $9.0 million in 2024 and averaged $299000.0.
- In the last 5 years, Pacira BioSciences' EBIAT surged by 166681.1% in 2023 and then plummeted by 142129.31% in 2024.
- Quarter analysis of 5 years shows Pacira BioSciences' EBIAT stood at -$5.1 million in 2021, then tumbled by 96.92% to -$10.1 million in 2022, then skyrocketed by 346.19% to $24.9 million in 2023, then crashed by 35.5% to $16.0 million in 2024, then plummeted by 66.14% to $5.4 million in 2025.
- Its EBIAT was $5.4 million in Q3 2025, compared to -$4.8 million in Q2 2025 and $4.8 million in Q1 2025.